fenofibrate has been researched along with Diabetes Mellitus, Type 1 in 14 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current, moderate-certainty evidence suggests that in a mixed group of people with and without overt retinopathy, who live with T2D, fenofibrate likely results in little to no difference in progression of diabetic retinopathy." | 9.41 | Fenofibrate for diabetic retinopathy. ( Inoue, K; Kataoka, SY; Kataoka, Y; Kawano, S; Lois, N; Watanabe, N, 2023) |
| "Current, moderate-certainty evidence suggests that in a mixed group of people with and without overt retinopathy, who live with T2D, fenofibrate likely results in little to no difference in progression of diabetic retinopathy." | 5.41 | Fenofibrate for diabetic retinopathy. ( Inoue, K; Kataoka, SY; Kataoka, Y; Kawano, S; Lois, N; Watanabe, N, 2023) |
| " Finally, we treated NOD mice with fenofibrate, a known activator of sulfatide biosynthesis, to evaluate the effect on experimental autoimmune diabetes development." | 3.88 | Abnormal islet sphingolipid metabolism in type 1 diabetes. ( Buschard, K; Claessens, LA; Dahl-Jørgensen, K; Gerling, IC; Hanssen, KF; Hasselby, JP; Holm, LJ; Kaur, S; Koeleman, BPC; Krogvold, L; Mathews, CE; Morgan, NG; Pociot, F; Roep, BO; Russell, MA, 2018) |
| "Fenofibrate-treated NOD mice had a more stable blood glucose, which was associated with reduced non-fasting and increased fasting blood glucose." | 1.51 | Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice. ( Bilgin, M; Buschard, K; Giacobini, JD; Hasselby, JP; Haupt-Jorgensen, M; Holm, LJ, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kataoka, SY | 1 |
| Lois, N | 1 |
| Kawano, S | 1 |
| Kataoka, Y | 1 |
| Inoue, K | 1 |
| Watanabe, N | 1 |
| Holm, LJ | 2 |
| Haupt-Jorgensen, M | 1 |
| Giacobini, JD | 1 |
| Hasselby, JP | 2 |
| Bilgin, M | 1 |
| Buschard, K | 2 |
| Abdel-Aziz, AM | 1 |
| Abozaid, SMM | 1 |
| Yousef, RKM | 1 |
| Mohammed, MM | 1 |
| Khalaf, HM | 1 |
| Krogvold, L | 1 |
| Kaur, S | 1 |
| Claessens, LA | 1 |
| Russell, MA | 1 |
| Mathews, CE | 1 |
| Hanssen, KF | 1 |
| Morgan, NG | 1 |
| Koeleman, BPC | 1 |
| Roep, BO | 1 |
| Gerling, IC | 1 |
| Pociot, F | 1 |
| Dahl-Jørgensen, K | 1 |
| Pearsall, EA | 1 |
| Cheng, R | 2 |
| Matsuzaki, S | 1 |
| Zhou, K | 1 |
| Ding, L | 1 |
| Ahn, B | 1 |
| Kinter, M | 1 |
| Humphries, KM | 1 |
| Quiambao, AB | 1 |
| Farjo, RA | 1 |
| Ma, JX | 2 |
| Chahande, S | 1 |
| Murthy, R | 1 |
| Zhang, J | 1 |
| Cheng, Y | 1 |
| Gu, J | 1 |
| Wang, S | 1 |
| Zhou, S | 1 |
| Wang, Y | 1 |
| Tan, Y | 1 |
| Feng, W | 1 |
| Fu, Y | 1 |
| Mellen, N | 1 |
| Ma, J | 1 |
| Zhang, C | 1 |
| Li, Z | 1 |
| Cai, L | 1 |
| Simó, R | 1 |
| Hernández, C | 1 |
| Hermans, MP | 1 |
| Chen, Y | 1 |
| Hu, Y | 1 |
| Lin, M | 1 |
| Jenkins, AJ | 1 |
| Keech, AC | 1 |
| Mott, R | 1 |
| Lyons, TJ | 1 |
| Abcouwer, SF | 1 |
| Engelen, W | 1 |
| Manuel-y-Keenoy, B | 1 |
| Vertommen, J | 1 |
| De Leeuw, I | 1 |
| Van Gaal, L | 1 |
| Letonturier, P | 1 |
| Hajós, P | 1 |
| Tornyossi, M | 1 |
3 reviews available for fenofibrate and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Fenofibrate for diabetic retinopathy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Mac | 2023 |
Advances in the medical treatment of diabetic retinopathy.
Topics: Blindness; Blood-Retinal Barrier; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Dia | 2009 |
Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.
Topics: Albuminuria; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Evidence-Based Medicine; Fenofibrate; | 2011 |
1 trial available for fenofibrate and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Effects of micronized fenofibrate and vitamin E on in vitro oxidation of lipoproteins in patients with type 1 diabetes mellitus.
Topics: Adult; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 1; Dosage Forms; Double-Blind Method | 2005 |
10 other studies available for fenofibrate and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Female; Fenofibrate; Homeostasis; Hypolipidemic A | 2019 |
Fenofibrate ameliorates testicular damage in rats with streptozotocin-induced type 1 diabetes: role of HO-1 and p38 MAPK.
Topics: Animals; Antioxidants; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Down-R | 2020 |
Abnormal islet sphingolipid metabolism in type 1 diabetes.
Topics: Adult; Animals; Autoimmunity; Case-Control Studies; Cell Proliferation; Cells, Cultured; Diabetes Me | 2018 |
Neuroprotective effects of PPARα in retinopathy of type 1 diabetes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Disease Models, Animal; Fenofib | 2019 |
Lipemia retinalis following systemic steroids for neurocysticercosis in a juvenile diabetic.
Topics: Adolescent; Anti-Inflammatory Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; | 2015 |
Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice.
Topics: Animals; Autophagy; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 2016 |
Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models.
Topics: Animals; Capillary Permeability; Cell Adhesion; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Dis | 2013 |
Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy.
Topics: Animals; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Fenofibrate; Hypoglycemic Agents; Male; PP | 2013 |
[Diabetes mellitus: types 1 & 2 increasingly similar].
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Mass Index; Child; Diabetes Complications; Diabetes Mel | 2006 |
Effect of lipanthyl in hyperlipoproteinaemic diabetic patients.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fe | 1989 |